Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Mature T Cell Lymphoma

Inclusion Criteria

• Patients must have histologically or cytologically confirmed relapsed/refractory CD30 low (< 10%) TCL: * Peripheral TCL not otherwise specified (PTCL NOS) * Angioimmunoblastic T cell lymphoma (AITL) * Hepato-splenic T cell lymphoma (HTCL) * Adult T cell leukemia/lymphoma (ATLL) * Enteropathy associated T cell lymphoma (EATL) * Natural killer (NK) T cell lymphoma (NK/TCL)
• At least 1 prior chemotherapy regimen
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2; ECOG performance status (PS) 3 will be permitted if the decreased PS is attributed to the lymphoma
• Absolute neutrophil count >= 1,000/mcL (unless documented bone marrow involvement with lymphoma)
• Platelet count >= 50,000/uL (unless documented bone marrow involvement with lymphoma)
• Total bilirubin =< 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULN even in patients with documented hepatic involvement with lymphoma
• Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN even in patients with documented hepatic involvement with lymphoma
• Serum creatinine clearance >= 30 ml/min
• At least 6 weeks from autologous stem cell transplantation
• At least 3 months from allogeneic stem cell transplantation and off immunosuppression and no evidence of graft versus host disease (GVHD)
• Previous treatment with brentuximab vedotin will be allowed if it was done 6 months prior to enrollment and was not refractory to or had progressive disease (PD) on brentuximab vedotin (BV)
• Measurable disease >= 1.5 cm seen on computed tomography (CT) scan and fludeoxyglucose F-18 (FDG) avid disease on positron emission tomography (PET) scan; splenomegaly measuring > 12 cm, if attributed to TCL and/or positive bone marrow involvement with lymphoma are also eligible
• Females of childbearing potential must have a negative serum or urine pregnancy test result within 7 days prior to the first dose of study treatment; women of childbearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) for the duration of study participation and for 6 months after completing treatment; should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately; males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drug
• Subjects must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Myocardial infarction within the past 6 months
• Patients who are receiving any other chemotherapy or investigational agents; radiation treatment will not be permitted during study treatment; patients can receive radiation therapy (XRT) 2 weeks prior to study drug administration or 4 weeks post study completion or discontinuation; steroids equivalent to prednisone 60 mg daily are permitted prior to study drug administration, but needs to be discontinued 1 day prior to BV administration; patients receiving steroids for lymphoma symptoms should have measurable disease as mentioned above on baseline scans
• Presence of central nervous system (CNS) involvement requiring active treatment
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin
• Cutaneous T cell lymphomas except transformed mycosis fungoides (MF)
• Prior treatment with brentuximab in the last 6 months or had refractory or progressive disease to prior BV treatment
• Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• History of progressive multifocal leukoencephalopathy (PML)
• Pregnancy or breast-feeding women; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
• A known history of human immunodeficiency virus (HIV)
• Presence of grade > 2 peripheral neuropathy or patients with the demyelinating form of Charcot-Marie-Tooth syndrome
• Prior malignancy within the past 3 years except non-melanoma skin cancer or other localized cancer treated with curative intent
• Patients with the following medical conditions that could affect their participation in the study: * Any active acute or chronic or uncontrolled infection * Liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis * Symptomatic cardiac disease, including congestive heart failure, coronary artery disease, and arrhythmias